Biomarker Analysis Services for Myelodysplasia
Alfa Cytology offers specialized biomarker analysis services tailored to support research and development in Myelodysplasia, with a focus on advancing drug discovery through preclinical development stages. Our comprehensive biomarker panel is designed to deepen understanding of Myelodysplasia pathophysiology, enabling the identification and characterization of molecular alterations relevant to disease mechanisms. Please note: all our services are strictly dedicated to drug discovery and preclinical research applications; we do not provide clinical diagnostic services.
Effective therapeutic intervention in Myelodysplasia begins with the robust discovery and identification of relevant biomarkers. Alfa Cytology’s biomarker discovery services are integral to drug development, enabling the detection of molecular signatures associated with disease pathogenesis. Our approach involves systematic screening of candidate genes, proteins, and molecular pathways, followed by rigorous validation processes to ensure specificity and relevance. Through high-throughput analyses and iterative validation, we facilitate the identification of biomarkers with potential utility in preclinical drug development pipelines.
Multi Omics: Employing a multi-omics approach, Alfa Cytology integrates cutting-edge genomics, transcriptomics, proteomics, and metabolomics technologies to provide a comprehensive analysis of biological systems associated with Myelodysplasia. This holistic evaluation supports the identification of DNA, RNA, protein, and metabolite biomarkers, uncovering the molecular complexity of disease pathways such as aberrant splicing, epigenetic dysregulation, and altered signaling cascades. Our multi-omics strategies enhance the resolution of disease-associated molecular alterations, supporting the elucidation of pathogenic mechanisms in Myelodysplasia.
Candidate Validation: Our candidate validation strategies encompass a suite of experimental and computational methods to assess the association of identified biomarkers with Myelodysplasia pathophysiology. Preliminary screening processes involve cross-referencing molecular candidates with disease-specific genetic, transcriptomic, and proteomic datasets. Criteria for prioritizing promising candidates include biological relevance to hematopoietic dysregulation, prevalence in disease models, and amenability to assay development. This rigorous approach ensures that only the most relevant biomarkers advance to subsequent stages of preclinical research.
Diverse Technological Platforms: Alfa Cytology offers custom assay development capabilities, leveraging a diverse array of technological platforms adaptable to specific research requirements. Our platforms include advanced immunoassay systems, mass spectrometry instrumentation, flow cytometry analyzers, molecular diagnostic tools, and digital histopathology and imaging systems. Each platform is optimized to accommodate the unique analytical needs of Myelodysplasia biomarker research.
Immunoassays: We develop and implement enzyme-linked immunosorbent assays (ELISA), chemiluminescent immunoassays, and multiplex bead-based immunoassays for the quantitative detection of protein biomarkers.
Mass Spectrometry: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is used for high-sensitivity quantification and characterization of proteins, peptides, and metabolites relevant to Myelodysplasia.
Flow Cytometry: Flow cytometry enables multiparametric analysis of cell surface and intracellular markers, supporting the identification of aberrant cell populations and protein expression profiles.
Molecular Diagnostics: We employ PCR, qPCR, and digital PCR for the detection of gene mutations, expression levels, and splicing variants in candidate biomarkers.
Histopathology And Imaging: Digital histopathology and advanced imaging techniques are utilized to visualize biomarker expression and localization within tissue samples, aiding in spatial and morphological analyses.
Rigorous Method Validation: All analytical methods undergo rigorous validation according to established guidelines, including assessment of specificity, sensitivity, accuracy, precision, linearity, and reproducibility. Our quality control measures encompass the use of reference standards, control samples, and periodic performance audits to ensure reliable and reproducible data output across platforms.
Our quantitative analysis capabilities enable precise measurement of biomarker levels across diverse sample types. We employ standardized protocols and calibration strategies to ensure data comparability and statistical robustness, supporting the generation of high-quality datasets for preclinical research applications.
Sample Analysis: We process a variety of sample types including cell lines, primary cells, bone marrow aspirates, peripheral blood, and tissue specimens. Each sample is handled using validated protocols that preserve molecular integrity and minimize pre-analytical variability. Stringent quality control checkpoints are implemented throughout the sample analysis workflow to ensure data reliability.
High Throughput Capabilities: Our high-throughput analytical platforms support multiplexed analysis, enabling simultaneous quantification of multiple biomarkers within a single sample. This approach maximizes efficiency, conserves valuable research material, and accelerates data acquisition for large-scale preclinical studies.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| DNA methyltransferase 3 alpha (DNMT3A) | DNA methyltransferase 3 alpha (DNMT3A) is an enzyme that catalyzes the transfer of methyl groups to cytosine residues in DNA, primarily at CpG dinucleotides. It is a member of the DNA methyltransferase family and plays a crucial role in establishing de novo DNA methylation patterns during development. DNMT3A-mediated methylation is essential for the regulation of gene expression, genomic imprinting, X-chromosome inactivation, and the maintenance of genome stability. The enzyme functions in both embryonic and adult tissues and is involved in various biological processes, including hematopoiesis and neuronal differentiation. | Alterations in DNMT3A, particularly somatic mutations, have been identified in various hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The presence of DNMT3A mutations is associated with disease classification, prognosis, and risk stratification in these conditions. DNMT3A mutation status is frequently assessed in clinical and research settings to aid in the characterization of myeloid neoplasms. Additionally, DNMT3A mutations have been detected in clonal hematopoiesis of indeterminate potential (CHIP), contributing to studies on age-related clonal expansion and risk assessment for hematologic diseases. |
| Janus kinase 2 (JAK2) | Janus kinase 2 (JAK2) is a non-receptor tyrosine kinase that plays a critical role in signal transduction for various cytokines and growth factors. Upon ligand binding to cytokine receptors, JAK2 becomes activated through trans-phosphorylation, leading to the phosphorylation of specific tyrosine residues on the receptor. This activation enables the recruitment and phosphorylation of signal transducer and activator of transcription (STAT) proteins, which then translocate to the nucleus to regulate gene expression. JAK2 is essential for hematopoiesis, immune function, and growth factor signaling, and is involved in the regulation of cell proliferation, differentiation, and survival. | JAK2, particularly the V617F mutation, is widely used as a biomarker in the diagnosis of myeloproliferative neoplasms (MPNs), such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The presence of the JAK2 V617F mutation is associated with constitutive kinase activity, leading to uncontrolled cell proliferation. Detection of this mutation aids in the classification of MPNs and can assist in distinguishing these conditions from other hematologic disorders. JAK2 mutation status may also provide prognostic information and inform therapeutic decisions in clinical practice. |
| KIT proto-oncogene, receptor tyrosine kinase (KIT) | The KIT proto-oncogene, receptor tyrosine kinase (KIT), encodes a type III transmembrane receptor tyrosine kinase that is activated by binding to its ligand, stem cell factor (SCF). Upon ligand binding, KIT undergoes dimerization and autophosphorylation, triggering downstream signaling pathways such as PI3K/AKT, RAS/RAF/MEK/ERK, and JAK/STAT. These pathways regulate critical cellular processes including proliferation, differentiation, survival, and apoptosis. KIT is essential for the development and function of several cell types, notably hematopoietic stem cells, melanocytes, germ cells, and interstitial cells of Cajal. | KIT is utilized as a biomarker in diagnostic and prognostic contexts, particularly in oncology. Immunohistochemical detection of KIT protein (CD117) is commonly used to identify gastrointestinal stromal tumors (GISTs), as most GISTs express KIT. KIT expression or mutation analysis also aids in the characterization of certain leukemias, melanomas, and mast cell diseases. The presence of KIT mutations can inform therapeutic decisions, especially regarding the use of tyrosine kinase inhibitors in tumors with activating KIT mutations. |
| WT1 transcription factor (WT1) | WT1 (Wilms tumor 1) is a zinc finger transcription factor that plays a critical role in the regulation of gene expression during embryonic development, particularly in the formation of the urogenital system, including the kidneys and gonads. WT1 modulates the transcription of target genes involved in cell growth, differentiation, and apoptosis. It is essential for normal nephrogenesis and gonadal development. WT1 can function as both a transcriptional activator and repressor, depending on the cellular context and the presence of specific cofactors. In addition to its developmental roles, WT1 is involved in the maintenance of podocyte function in the adult kidney and has been implicated in the regulation of mesenchymal-to-epithelial transitions. | WT1 is used as a biomarker in various clinical and research settings. It is commonly employed in the diagnosis and classification of certain tumors, such as Wilms tumor, mesothelioma, and serous carcinomas of the ovary, due to its high expression in these malignancies. Immunohistochemical detection of WT1 protein assists in distinguishing between tumor types and subtypes, especially in cases where morphological features overlap. Additionally, WT1 mRNA levels are monitored in hematological malignancies, such as acute myeloid leukemia, for the assessment of minimal residual disease and disease progression. |
| fms related receptor tyrosine kinase 3 (FLT3) | Fms related receptor tyrosine kinase 3 (FLT3) is a member of the class III receptor tyrosine kinase family. It is predominantly expressed on hematopoietic progenitor cells and plays a critical role in the regulation of proliferation, differentiation, and survival of these cells. Upon binding to its ligand (FLT3 ligand), the receptor undergoes dimerization and autophosphorylation, initiating downstream signaling pathways such as the PI3K/AKT, RAS/MAPK, and STAT5 pathways. These signaling cascades contribute to the maintenance and expansion of early hematopoietic cells in the bone marrow. | FLT3 is utilized as a biomarker in hematological malignancies, particularly in acute myeloid leukemia (AML). Mutations in the FLT3 gene, including internal tandem duplications (ITD) and point mutations in the tyrosine kinase domain (TKD), are frequently detected in AML patients. The presence and type of FLT3 mutations are associated with disease prognosis and can inform risk stratification. Additionally, FLT3 mutation status is used to guide therapeutic decision-making, including the consideration of FLT3 inhibitor therapies. |
| isocitrate dehydrogenase (NADP(+)) 1 (IDH1) | Isocitrate dehydrogenase (NADP(+)) 1 (IDH1) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, producing NADPH from NADP+ in the process. This reaction occurs in the cytoplasm and peroxisomes and is a key step in cellular metabolic pathways, including the citric acid cycle and lipid metabolism. The NADPH generated by IDH1 is important for cellular redox balance and biosynthetic reactions, including fatty acid and cholesterol synthesis, as well as protection against oxidative stress. | Mutations in the IDH1 gene, particularly the R132H substitution, are frequently detected in certain types of gliomas and other tumors such as acute myeloid leukemia (AML) and cholangiocarcinoma. The presence of IDH1 mutations is used in clinical practice to assist in the diagnosis, classification, and prognostication of these tumors. IDH1 mutation status can help distinguish between tumor subtypes, inform prognosis, and guide therapeutic decision-making, as some targeted therapies have been developed for IDH1-mutant malignancies. |
| isocitrate dehydrogenase (NADP(+)) 2 (IDH2) | Isocitrate dehydrogenase (NADP(+)) 2 (IDH2) is a mitochondrial enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate, producing NADPH in the process. This reaction is a key step in the tricarboxylic acid (TCA) cycle, which is central to cellular energy metabolism. NADPH generated by IDH2 is essential for maintaining cellular redox balance and for biosynthetic reactions. IDH2 activity contributes to the regulation of oxidative stress and mitochondrial function. | Mutations in the IDH2 gene, particularly at specific arginine residues (such as R140 and R172), have been identified in various malignancies, including acute myeloid leukemia (AML) and certain gliomas. The presence of these mutations can be detected in tumor tissue or, in some cases, in circulating DNA, and is used to assist in the diagnosis and classification of these cancers. Additionally, detection of IDH2 mutations can inform prognosis and may guide therapeutic decisions, especially in contexts where targeted inhibitors of mutant IDH2 are available. |
| nucleophosmin 1 (NPM1) | Nucleophosmin 1 (NPM1) is a ubiquitously expressed nucleolar phosphoprotein involved in multiple cellular processes. It plays a central role in ribosome biogenesis by facilitating the assembly and transport of preribosomal particles from the nucleolus to the cytoplasm. NPM1 also functions in centrosome duplication, regulation of the ARF-p53 tumor suppressor pathway, and response to cellular stress. It exhibits chaperone activity, assisting in the proper folding and transport of proteins and nucleic acids. NPM1 is known to shuttle between the nucleus and cytoplasm, and its localization is regulated by specific nuclear localization and export signals. | NPM1 is frequently used as a biomarker in the context of acute myeloid leukemia (AML). Mutations in the NPM1 gene, particularly those leading to aberrant cytoplasmic localization of the protein, are among the most common genetic alterations in adult AML. The presence of NPM1 mutations has been utilized for diagnostic classification, risk stratification, and monitoring of minimal residual disease in AML patients. Detection of NPM1 mutations is typically performed using molecular assays on patient samples. |
| splicing factor 3b subunit 1 (SF3B1) | Splicing factor 3b subunit 1 (SF3B1) is a core component of the spliceosome, specifically the U2 small nuclear ribonucleoprotein (snRNP) complex. SF3B1 plays a critical role in pre-mRNA splicing by facilitating the recognition of the branch point sequence during spliceosome assembly. Through its interactions with other splicing factors, SF3B1 contributes to the accurate removal of introns and the joining of exons, which is essential for generating mature messenger RNA transcripts. Mutations in SF3B1 can alter splicing fidelity and have been associated with aberrant splicing events. | SF3B1 is frequently mutated in several cancer types, including myelodysplastic syndromes, chronic lymphocytic leukemia, and uveal melanoma. The presence of SF3B1 mutations can assist in disease classification, risk stratification, and may provide prognostic information in these contexts. Detection of SF3B1 mutations is utilized in molecular diagnostic panels to aid in the characterization of hematologic malignancies and certain solid tumors. |
| tumor protein p53 (TP53) | Tumor protein p53 (TP53) encodes a transcription factor that plays a critical role in regulating the cell cycle, maintaining genomic stability, and inducing apoptosis in response to cellular stress or DNA damage. Upon activation, p53 can initiate the transcription of target genes involved in cell cycle arrest, DNA repair, senescence, and programmed cell death. This function helps prevent the propagation of cells with damaged DNA, thereby acting as a key tumor suppressor. TP53 activity is tightly regulated by various mechanisms, including interaction with MDM2, which targets p53 for proteasomal degradation under normal conditions. | TP53 is frequently mutated in a wide range of human cancers. The presence of TP53 mutations or alterations in its expression can be detected in tumor tissue and, in some cases, circulating DNA. Assessment of TP53 status is used in oncology to provide information about tumor characterization, prognosis, and, in certain contexts, to inform therapeutic decision-making. For example, TP53 mutations are associated with poor prognosis in several cancer types, and their detection can contribute to risk stratification and disease monitoring. |
Explore Research Opportunities with Alfa Cytology. Our biomarker research services offer a comprehensive suite of capabilities for Myelodysplasia, supporting exploratory studies and preclinical drug development. Please note that all biomarkers discussed are research targets only; we do not claim these as validated or mandatory markers for any application. Our focus is exclusively on preclinical research, and we maintain strict scientific objectivity throughout our collaborations.
We invite you to connect with Alfa Cytology to discuss collaborative opportunities in exploratory biomarker research for Myelodysplasia. Our team is dedicated to advancing scientific knowledge and fostering research partnerships—let’s explore the frontiers of biomarker discovery together.
Make Order
Experimental Scheme
Implementation
Conclusion
Myelodysplasia
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.